Keywords
How to Cite
Abstract
Disbalance of bone homeostasis, associated with malfunctioning of RANK/RANKL/OG system underlies the oncological processes such as the destruction of bone, metastasis development, tumor progression. Pathological activity of system was described in such conditions, as breast cancer, prostate cancer, multiple myeloma, squamous cell carcinoma, Hodgkin’s disease, and also metastasis in bones from lung cancer and other malignant diseases. In the literature, there is evidence of involvement of RANK/RANKL/OPG system in the pathogenesis of bone tumors (osteosarcoma, giant cell tumor of bone, chondroblastoma). Experimental data show that RANKL inhibitors can play a role in reducing tumor-induced lesions of bone in multiple myeloma, breast cancer, prostate cancer and lung cancer. Also this review presents data from clinical studies of the drug efficacy targeted on RANK/RANKL/OPG system and results of authors’ study of the levels of this system’s components and proinflammatory cytokines in blood serum of primary bone sarcoma patients.References
Кушлинский Н.Е., Тимофеев Ю.С., Соловьев Ю.Н. и др. Компоненты системы RANK/RANKL/OPG, ИЛ-6, ИЛ-8, ИЛ-16, ММП-2 и кальцитонин в сыворотке крови больных с новообразованиями костей // Бюлл. экспер. биол. мед. - 2014. - Т. 157. № 4. - С. 522-526.
Armstrong A.P., Miller R.E., Jones J.C. et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes // Prostate. - 2008. - Vol. 68. - P. 92-104.
Body J.J., Greipp P., Coleman R.E. et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases // Cancer. - 2003. - Vol. 97. - P. 887-892.
Bucay N., Sarosi I., Dunstan C.R. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification // Genes and Development. - 1998. - Vol. 12. N 9. P. 1260-1268.
Choi H.J., Park Y.R., Nepal M. et al. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kB signaling pathways // Eur. J. Pharmacol. - 2010. - Vol. 636. N 1-3. - P. 28-35.
Clinical Trials.gov. Bethesda (MD): NIH. Single ascend-ing-dose study to characterize the safety, pharmacokinetics, and pharmacodynamics of CEP-37251 in healthy postmenopausal women. 2010. Available from: http://clinicaltrials.gov/show/NCT01159873.
Coleman R.E., Major P., Lipton A. et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid // J. Clin. Oncol. - 2005. - Vol. 23. - P. 4925-4935.
Costa-Rodrigues J., Teixeira C.A., Fernandes M.H. Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: is RANKL/RANK signalling really important? // Clin. Exp. Metastasis. - 2011. - Vol. 28 (6). - P. 505-514.
Crockett J.C., Rogers M.J., Coxon F.P. et al. Bone remodeling at a glance // J. Cell Sci. - 2011. - Vol. 124. Suppl. 7. - P. 991-998.
Datta H.K., Ng W.F., Walker J.A. et al. The cell biology of bone metabolism // J. Clin. Pathol. - 2008. - Vol. 61. Suppl. 5. - P. 577-587.
Fizazi K., Lipton A., Mariette X. et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates // J. Clin. Oncol. - 2009. - Vol. 27. - P. 1564-1571.
Fizazi K., Carducci M., Smith M. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study // Lancet. - 2011. - Vol. 377. - P. 813-822.
Furuya D., Kaneko R., Yagihashi A. et al. Immuno-PCR assay for homodimeric osteoprotegerin // Clin. Chem. - 2001. - Vol. 47. - P. 1475-1477.
Giuliani N., Colla S., Sala R. et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease // Blood. - 2002. - Vol. 100. - P. 4615-4621.
Hannon R., Eastell R. Preanalytical variability of biochemical markers of bone turnover // Osteoporos. Int. - 2001. - Vol. 1(Suppl. 6). P. 30-40.
Hawa G., Brinskelle-Schmal N., Glatz K. et al. Immunoassay for soluble RANKL (receptor activator of NF-B ligand) in serum // Clin. Lab. - 2003. - Vol. 49. P. 461-463.
Henry D.H., Costa L., Goldwasser F. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma // J. Clin. Oncol. - 2011. - Vol. 29. - P. 1125-1132.
Hsu C.J., Lin T.Y., Kuo C.C. et al. Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration // J. Cell. Biochem. - 2010. - Vol. 111(1). - P. 138-47. doi: 10.1002/jcb.22677.
Jones D.H., Nakashima T., Sanchez O.H. et al. Regulation of cancer cell migration and bone metastasis by RANKL // Nature. - 2006. - Vol. 440. - P. 692-696.
Jorgensen H.L., Kusk P., Madsen B. et al. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios // J. Bone Miner. Metab. - 2004. - Vol. 22. - P. 132-138.
Komori T. Regulation of osteoblast differentiation by RUNX2 // Osteoimmunology. - 2010. - Vol. 658. Suppl. 1. - P. 43-49.
Kong Y.Y., Boyle W.J., Penninger J.M. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development // Immunol. Cell Biol. - 1999. - Vol. 77. N 2. - P. 188-193.
Kudlacek S., Schneider B., Woloszczuk W. et al. Serum levels of osteoprotegerin increase with age in a healthy adult population // Bone. - 2003. - Vol. 32. - P. 681686.
Lee J.A., Jung J.S., Kim D.H. et al. RANKL expression is related to treatment outcome of patients with localized, high -grade osteosarcoma // Pediatr. Blood Cancer. - 2011. - Vol. 56(5). - P. 738-743.
Liu B., Yu S.F., Li T.J. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts // J. Oral. Pathol. Med. - 2003. - Vol. 32(6). - P. 367-375.
Luo J.L., Tan W., Ricono J.M. et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin // Nature. - 2007. - Vol. 446. - P. 690-694.
Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis // Endocrine Reviews. - 2000. - Vol. 21. - N 2. - P. 115-137.
Maruyama T., Fukushima H., Nakao K. et al. Processing of the NF-kB2 precursor p100 to p52 is critical for RANKL-induced osteoclast differentiation // J. Bone Miner. Res. - 2010. - Vol. 25. N 5. - P. 1058-1067.
Mori K., Le Goff B., Berreur M. et al. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B // J. Pathol. - 2007. - Vol. 211(5). - P. 555-562.
Mori K., Ando K., Heymann D., Rédini F. Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? // Histol. Histopathol. - 2009. - Vol. 24(2). - P. 235-242.
Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities // Nat. Rev. Cancer. - 2002. - Vol. 2. - P. 584-593.
Raggatt L.J., Partridge N.C. Cellular and molecular mechanisms of bone remodeling // J. Biol. Chem. - 2010. - Vol. 285. Suppl. 33. - P. 25103-25108.
Riggs B.L., Khosla S., Atkinson E.J. et al. Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency // Osteoporos. Int. - 2003. - Vol. 14. - P. 728-733.
Roodman G.D., Dougall W.C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma // Cancer Treat. Rev. - 2008. - Vol. 34. - P. 92-101.
Rousseau J., Escriou V., Lamoureux F. et al. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models // J. Bone Miner. Res. - 2011. - Vol. 26(10). - P. 2452-2462.
Rucci N. Molecular biology of bone remodeling // Clin. Cases Miner. Bone Metab. - 2008. - Vol. 5. Suppl. 1. - P. 49-56.
Rucci N., Millimaggi D., Mari M. et al. Receptor activator of NF-kappaB ligand enhances breast cancerinduced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147 // Cancer Res. - 2010. - Vol. 70. - P. 6150-6160.
Sagalovsky S., Schonert M. RANKL-RANK-OPG system and bone remodeling: a new approach to the treatment of osteoporosis // Clin. Exp. Pathol. - 2011. - Vol. 10. Suppl. 2. - P. 146-153.
Sasaki A., Ishikawa K., Haraguchi N. et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis // Ann. Surg. Oncol. - 2007. - Vol. 14. - P. 1191-1199.
Schramek D., Leibbrandt A., Sigl V. et al. Osteoclast differentiation factor RANKL controls development of progestin- driven mammary cancer // Nature. - 2010. - Vol. 468. - P. 98-102.
Stopeck A.T., Lipton A., Body J.J. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study // J. Clin. Oncol. - 2010. - Vol. 28. - P. 5132-5139.
Tan W., Zhang W., Strasner A. et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signaling // Nature. - 2011. - Vol. 470. - P. 548-553.
Taylor R., Knowles H.J., Athanasou N.A. Ewing sarcoma cells express RANKL and support osteoclastogenesis // J. Pathol. - 2011. - Vol. 225(2). - P. 195-202.
Teitelbaum S.L. Bone resorption by osteoclasts // Science. - 2000. - Vol. 289. N 5484. - P. 1504-1508.
Terpos E., Szydlo R., Apperley J.F. et al. Soluble receptor activator of nuclear factor kappaB ligandosteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index // Blood. - 2003. - Vol. 102. - P. 1064-1069.
Totsuka T., Kanai T., Nemoto Y et al. RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis // J. Immunol. - 2009. - Vol. 182. - P. 6079-6087.
Vaira S., Alhawagri M., Anwisye I. et al. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice // J. Clin. Invest. - 2008. - Vol. 118. N 6. - P. 2088-2097.
van de Wetering de Rooij J., Lyssens C. et al. Safety, pharmacokinetics and efficacy of anti-RANKL nanobody ALX-0141 in healthy postmenopausal women // Ann. Rheum. Dis. - 2011. - Vol. 70. Suppl. 3. - P. 136.
Vega D., Maalouf N.M., Sakhaee K. The Role of Receptor Activator of Nuclear Factor-B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications // J. Clin. Endocrinol. Metab. - 2007. - Vol. 92(12). - P. 4514-4521.
Whyte M.P., Mumm S. Heritable disorders of the RANKL/ OPG/RANK signaling pathway // J. Musculoskel. Neuronal Interact. - 2004. - Vol. 4. N 3. - P. 254-267.
Whyte M.P., Obrecht S.E., Finnegan P.M. et al. Osteoprotegerin deficiency and juvenile Paget’s disease // N. Engl. J. Med. - 2001. - Vol. 347. N 3. - P. 175-184.
Whyte M.P., Singhellakis P.N., Petersen M.B. et al. Juvenile Paget’s disease: the second reported, oldest patient is homozygous for the TNFRSF11B «Balkan» mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels // J. Bone Miner. Res. - 2007. - Vol. 22. N 6. - P. 938-946.
Whyte M.P., Totty W.G., Novack D.V. et al. Camurati-Engelmann disease: unique variant featuring a novel mutation in TGFß1 encoding transforming growth factor beta
and a missense change in TNFSF11 encoding RANK ligand // J. Bone Miner. Res. - 2011. - Vol. 26. N 5. - P. 920-933.
Wilson S.R., Petersilso C., Saftig P., Bromme D. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption // J. Biol. Chem. - 2009. - Vol. 284. Suppl. 4. - P. 2584-2592.
Xiong J., Onal M., Jilka R.L. et al. Matrix-embedded cells control osteoclast formation // Nat. Med. - 2011. - Vol. 17. - P. 1235-1241.
Zhang Y.H., Heulsmann A., Tondravi M.M. et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways // J. Biol. Chem. - 2001. - Vol. 276. - P. 563-568.
Zhang J., Lu Y., Dai J. et al. In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer // Prostate. - 2004. - Vol. 59. - P. 360-369.
Zhao Q., Wang X., Liu Y. et al. NFATc1: functions in osteoblasts // Int. J. Biochem. Cell Biol. - 2009. - Vol. 42. Suppl. 5. - P. 576-579.
Zheng Y., Zhou H., Brennan K. et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis // Bone. - 2007. - Vol. 40. - P. 471-478.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...